Abstract
Rosiglitazone, a thiazolidinedione (TZD), is a selective peroxisome proliferator-activated receptor-gamma (PPAR-) agonist widely used in the treatment of type 2 diabetes mellitus (1). In addition to effectively controlling glycemia by improving insulin sensitivity, TZDs have pleiotropic effects on endothelial function, lipids, blood pressure, and inflammation (2). Whether the improvements in various risk factors reduce cardiovascular morbidity and mortality is a matter of debate (3,4). Data on the effect of rosiglitazone on blood pressure, peripheral edema, blood lipids, peritoneal membrane characteristics, and oxidative stress on the peritoneal dialysis (PD) population are scarce or lacking in the current literature (5,6).
Original language | English |
---|---|
Pages (from-to) | 108-111 |
Number of pages | 4 |
Journal | Peritoneal Dialysis International |
Volume | 29 |
Issue number | 1 |
Publication status | Published - 2009 |
Keywords
- Rosiglitazone
- peritoneal dialysis
- short-term effect